N-[5-hydroxy-5-[7-[(2-hydroxy-5-oxocyclopenten-1-yl)amino]-7-oxohepta-1,3,5-trienyl]-2-oxo-7-oxabicyclo[4.1.0]hept-3-en-3-yl]-2,4,6-trimethyldeca-2,4-dienamide

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: N-[5-hydroxy-5-[7-[(2-hydroxy-5-oxocyclopenten-1-yl)amino]-7-oxohepta-1,3,5-trienyl]-2-oxo-7-oxabicyclo[4.1.0]hept-3-en-3-yl]-2,4,6-trimethyldeca-2,4-dienamide
• 化学式: C₃₁H₃₈N₂O₇
• 分子量: 550.6
• InChiKey: TWWQHCKLTXDWBD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  40
• 可旋转键数：
  12
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  145
• 氢给体数：
  4
• 氢受体数：
  7

文献信息

• [EN] METHODS OF TREATMENT OF CANCER ASSOCIATED WITH CENTROSOME AMPLIFICATION<br/>[FR] MÉTHODES DE TRAITEMENT DU CANCER ASSOCIÉ À UNE AMPLIFICATION DE CENTROSOMES
  申请人：INST DE MEDICINA MOLECULAR

  公开号：WO2020130863A1

  公开（公告）日：2020-06-25

  This invention relates to the finding that centrosome amplification (CA) renders cancer cells more sensitive to certain anti-cancer compounds. The invention provides methods of treating cancer that displays centrosome amplification (CA) by administering a CA selective agent. Also provided are methods of screening for a CA selective agent comprising determining the effect of a test compound on the expression of a panel of CA associated genes in the cell and methods of determining the sensitivity of a cancer cell to a CA selective agent comprising determining the expression of a panel of CA associated genes in the cancer cell. Other aspects of the invention relate to measuring the expression of a panel of CA associated genes in order to assess a cancer condition in an individual or to assess genomic instability in a cancer cell.